http://marijuanaindex.com/2015/03/investing-marijuana-microcap-stocks/ DigiPath Labs Adds Green Life as New Client November 18, 2015 DigiPath Inc. (OTCQB: DIGP), a provider of reliable testing, education, training, and unbiased news coverage to the cannabis industry, recently announced the addition of Green Life Productions as a new clients for its DigiPath Labs subsidiary. By leveraging its cutting-edge testing equipment and methodologies, the company will provide extensive testing services designed to ensure that the client"s products are safe and efficacious. "Our goal at Green Life Productions is to raise the ethical and ecological standards for medical cannabis growing,†said cofounders Steve Cantwell and Kouanin Villa in a press release announcing the deal. "DigiPath Labs" commitment to standardization and safety were a perfect fit for our permaculture philosophy. We also love their 48-hour turnaround which allows us to quickly get our products on the shelves of local dispensaries.†Green Life Productions grows a number of different cannabis strains using a no-till living soil system that reduces ecological impact and enhances patient safety. Under the agreement, DigiPath Labs will test a variety of these strains for moisture content, potency, terpenoids, foreign matter, microbials, mycotoxins, heavy metals, and pesticide residues in order to ensure that they are safe for consumption by patients and produce the desired effects. "We have been advocating for a more scientific approach for years, and now we"re finding likeminded growers, such as Steve and Kouanin, who are eager to receive the unbiased information we can offer about their products and use that data to continually refine growing techniques,†says DigiPath CEO Todd Denkin in the same press release announcing the deal. "This is an exciting time to be at the forefront of the medical cannabis industry.†To learn more, visit the company"s website at www.digipath.com. Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/. Signal Bay Inc. (OTC: SGBY), a leading provider of cannabis consulting, research, data, operations, and laboratory services, continues to expand its client base throughout the country and has recently focused their attention to Maryland and Oregon. In the past two months the company has acquired a cannabis research & testing laboratory in Bend, Oregon, executed a strategic partnership with another research & testing laboratory in Medford, Oregon, and signed three new consulting clients in Maryland in Montgomery, Frederick and Prince George"s counties. In this article, we"ll take a closer look at the company"s progress in signing new clients, its unique approach to these industry verticals, and the opportunity for cannabis investors to get involved in a diversified and rapidly growing company at a reasonable price. 100% Consulting Success Rate On October 15 of this year Signal Bay announced the execution of three new consulting agreements with Maryland-based clients Under the terms of the agreements, the company flew their team of experts from the Cannabis Consultant Marketplace to Maryland and assisted these companies to complete their business plans and licensing applications in order to open medical marijuana dispensaries, processing and cultivation facilities. Applicants will be notified in January 2016 and successful entrepreneurs will be awarded a Stage 1 license approval and will have 365 days to obtain a formal license from the state. Since 2014, the company"s founders have a 100% success rate in securing licenses for their clients, something that sets Signal Bay apart from many other cannabis consultants. The high level of success stems from its broad network of over 500 professionals across the country that are members of its Cannabis Consultant Marketplace, which launched in July of this year By working with these professionals from across the country, the company is able to provide an unparalleled breadth of services, while maintaining deep expertise. The consulting segment of the cannabis industry continues to produce the most explosive growth given the high demand for licensing services. According to a FY2014 Viridian Capital & Research report, consulting services were the fastest growing segment of the cannabis industry in 2014 with a 169.9% growth rate. Companies also operating in the consulting space include Chuma Holdings, Inc. (OTC: CHUM) and General Cannabis Corp. (OTC: CANN). By comparison, biotechnology companies, like Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) (which IPO"d earlier this year), were the second fastest growing at 84.6%. Diversification into Lab Testing Signal Bay has diversified recently beyond cannabis consulting into another rapidly growing segment of the cannabis industry – laboratory testing services. In late October, the company announced a Memorandum of Understanding with Smith Scientific Industries Inc. that involves a strategic investment into the Kenevir Research cannabis laboratory testing business. Established in 2013, the Oregon based laboratory is well positioned to capitalize on growing demand of testing services following the introduction of adult-use legalization on October 1st. The strategic agreement with Kenevir Research comes shortly after the company completed the acquisition of Bend, Oregon-based Cannalytical Research in September 2015. With a history of providing state-mandated compliance testing in the medical marijuana space since May 2014, the laboratory is already generating recurring cash flows. Combined, these two deals represent geographic coverage of about two thirds of the state"s $10 million annual laboratory testing market. According to GreenWave Advisors, a comprehensive independent research firm focused on the emerging legal cannabis industry, the cannabis lab testing market is expected to generate upwards of $850 million in revenue by 2020. GreenWave Founder Matthew Karnes also called it the "most attractive subsector of the industry.†Looking Ahead Signal Bay has built up a strong presence in both cannabis consulting – the fastest growing subsector in 2014 – and laboratory testing – the most attractive subsector moving forward. With this diversified presence, the company provides investors with high-margin exposure to multiple areas of the industry that are quickly expanding. The company"s modest $5 million market cap also compares favorably to others in the industry and could be poised for continuing managed growth in 2016. For more information, visit the company"s website at www.signalbayinc.com. Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/. DigiPath Inc. (OTC: DIGP), a leading provider of cannabis testing through its DigiPath Labs subsidiary, has been steadily expanding its client base since opening its flagship cannabis testing lab in Las Vegas, Nevada. On November 9th, the company announced a deal with Las Vegas Herbal Growers to perform all of their cannabis safety and potency testing. DigiPath Labs will test the material for moisture content, potency, terpenoids, foreign matter, microbials, mycotoxins, heavy metals, and pesticide residue using its top-of-the-line equipment and exacting standard operating procedures in order to meet the State of Nevada"s stringent standards. "We know we"d found the right testing lab when we met with DigiPath Labs,†said the owner of Las Vegas Herbal Growers in the press release announcing the deal. "Like us, they truly care about patient safety, and the care they put into setting up and operating the lab proves it. We look forward to working with DigiPath Labs for many years to come.†The move follows similar contracts signed earlier this year with local growers. As of early October, the State of Nevada has permitted three dispensaries to open and certified another 52 through the Department of Public and Behavioral Health. The market for cannabis testing services could expand even further in November of 2016, with an initiative to legalize adult-use marijuana widely expected to pass by pollsters. "We expect that the growth in the Nevada cannabis industry will be exponential over the next few years,†said DigiPath Inc. CEO Todd Denkin in a past press release announcing new clients in late-September. "And because Nevada has the strictest testing requirements in the country, everything will need to be tested before it reaches users. These regulations should make DigiPath Labs an essential player in the statewide cannabis community.†DigiPath Inc. Chief Science Officer Dr. Cindy Orser, Ph.D., has also been pushing for unified cannabis testing standards throughout the country. After working with Nevada to draft its testing standards, she attended the Conference of Western Attorneys General to adopt those standards in other states that have legalized the drug. The hope is to create a unified system rather than voluntary standards that remain commonplace across the country. Shares of DigiPath Inc. have been trading relatively even at between $0.17 and $0.20 over the past couple of weeks as the company continues to make progress operationally. Legal Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Important factors that could cause these differences include, but are not limited to, the demand for the company"s services, governmental regulation of the cannabis industry, and the company"s ability to execute its business plan. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claim to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, has been compensated for its services in the form of cash and equity securities by DigiPath. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/. The legal cannabis industry is expected to reach $11 billion in size by 2019 thanks to ongoing legalization of marijuana on a state level, according to ArcView Market Research. While a number of studies have demonstrated the plant"s efficacy in treating medical conditions like cancer pain and childhood epilepsy, researchers are quickly discovering just how little they know about different cannabis strains and their mechanisms of action. In this article, we"ll take a look at some of these issues, some near-term solutions, and potential long-term goals to ensure the long-term health of the industry. Inaccurate Labeling of Strains In a recent blog post, DigiPath Inc. (OTCQB: DIGP) Chief Science Officer Dr. Cindy Orser, Ph.D., highlighted a series of studies that show that the identity of marijuana strains cannot be reliably inferred from their strain name or reported ancestry. Covert amateur plant breeders and the creation of so-called hybrid strains over the past several decades have led to a lot of confusion among participants in the rapidly growing multi-billion dollar industry. These problems were perhaps best illustrated in a recent article, "The Genetic Structure of Marijuana and Hemp†that was published in PLOS ONE, which shows that cannabis samples were found to be more genetically similar to samples with different names than to samples with the same name. In other words, the labeling of cannabis strains was more inaccurate than accurate due to poor strain naming conventions. These are troubling dynamics for those that rely on specific concentrations of cannabinoids to provide medicinal benefits. For instance, someone that"s consuming marijuana derivatives for the CBD content may be adversely affected by significant THC content, which may produce a greater psychoactive response and related side-effects. The reality is that people are simply making up names, applying them to whichever strain they come across, and voila you have the most popular strain on the market and can charge more for it. A brilliant marketing strategy, and one that would not work in other industries. The difference in concentrations could also become a problem when presenting the drug for regulatory approvals, as samples will need to be consistent and standardized in order to have proper testing conducted on them. Entourage Effects in Cannabis Cannabis chemistry goes well beyond household cannabinoids, like THC and CBD, with more than 60 different cannabinoids present in most plants. The interactive synergies between marijuana compounds has been coined the "entourage effect†and new science suggests that THCs and CBDs in isolation may be insufficient for most medical conditions, which is troubling given that many synthetic marijuana derivatives focus on isolating them. In a 2011 survey on forms of consumption, only 1.8% of 953 patients preferred synthetic THC pharmaceuticals to inhaled or infused methods. There are many potential reasons behind these trends – such as the fact that THC-only pills can take hours to deliver relief as opposed to fast-acting inhaled or infused methods, but the chemical diversity found in inhaled or infused methods is likely a key driver behind greater therapeutic benefits. For instance, a recent Leafly report highlights that the terpene myrcene reduces resistance in the blood-brain barrier, enabling easier passage of other beneficial chemicals. Similarly, pinene helps counteract compromised cognition and memory loss caused by THC. Specific concentrations of cannabinoids may also be better for certain indications, such as the combination of THC and CBN for enhanced sedating effects. Measuring Cannabinoid Content The need for accurate identification of cannabis strains has become apparent, but a well-funded unified scientific effort would be required to create a classification system. In the meantime, the cannabis industry may have to rely on laboratory testing to develop so-called potency profiles, metabolic profiles, or "chemo†profiles of a particular cannabis crop in order to determine the appropriate strain naming conventions and drug content. With the cannabis industry expected to rapidly grow over the coming quarters, investors in the traditional laboratory testing or diagnostics space, including companies like PositiveID Corporation (OTCQB: PSID) or Psychemedics Corp. (NASDAQ: PMD), may want to consider DigiPath Inc. (OTCQB: DIGP) and the cannabis testing space as an opportunity to diversify into a new industry that"s well-positioned for substantial future growth. The rise of cannabis testing requirements could also make cannabinoid profiling important for dispensaries, such as those operated by Kaya Holdings Inc. (OTCQB: KAYS) in Oregon, or dispensaries that are already served by companies like DigiPath Labs in Nevada. Looking Ahead The cannabis testing industry is likely to only grow in importance as researchers realize just how little is understood about the breeding and content of cannabis plants. With over a million dollars invested in laboratory equipment, a company like DigiPath Labs is well positioned to support the long-term growth of the industry. For more information, visit the company"s website at www.digipathlabs.com. Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/. Cannabis users experience a wide range of physical and mental effects depending on a person"s age, genetics, diet, and other factors, which means that a strain"s purported benefits or attributes may not apply to every individual that consumes the drug. MyDx Inc. (OTCQB: MYDX) has developed an innovative chemical sensor that instantly creates a chemical profile of the drug and automatically learns what chemical make-up helps patients achieve their desired outcome – whether it is euphoria or pain relief. With an affordable price point and convenient mobile app, the technology empowers individuals to take health into their own hands and ensure they are consuming safe and effective products. In this article, we will take a look at the company"s innovative technology and some new additions that have turned it into a powerful tool for both medical and recreational users, as well as potentially anyone in the future as it expands beyond the cannabis market. Medical Recommendations The cannabis industry can be difficult to navigate when it comes to determining the right strains to address certain ailments. While strains like Charlotte"s Web may be well-studied for conditions like epilepsy, countless others strains are misleadingly named and there is very little standardization throughout geographic regions. These dynamics make it difficult for medical marijuana patients to get the medicine they need to alleviate certain conditions. MyDx leverages the power of big data and machine learning to determine what strains may be a good fit to address specific medical issues. For instance, the app collects data from thousands of other MyDx users to determine how certain cannabinoid profiles work in alleviating specific conditions. Strains with a similar profile – verified through a chemical analysis – may be recommended for a condition where many other users reported a benefit. The technology addresses two of the industry"s big concerns – a lack of standardized strains and a lack of data on what works best for certain conditions. Click Here: Watch an Exclusive Interview with MyDx Management In addition to making these suggestions, the technology automatically learns how a given user responds to various cannabinoid profiles in order to predict how they"ll respond to entirely new strains of cannabis before trying them. A user who has recorded sensitivity to THC in the past, for instance, may automatically be warned that a THC-heavy strain may cause issues for them. Commercialization Opportunities MyDx plans on letting advertisers promote their strains in the Recently Tested section of the app or in the "feeling search algorithm†by sharing them with the community. For instance, a local dispensary in Colorado may have their strain analyzed and promoted to specific users within the state that may be seeking exactly that type of feeling or ailment relief. By combining hardware with software, this model also puts the company on the same playing field as tech companies like FitBit Inc. (NYSE: FIT), Lifelogger Technologies Corp. (OTC: LOGG), and bBooth Inc. (OTC: BBTH) in terms of personal tracking and hardware integration. These companies have developed hardware technologies that they monetize through software over time using a crowd-sourced user base model similar to MyDx. MyDx is also targeting end markets beyond cannabis in the near future, including water, air quality, and food testing on a consumer level, which opens up the market to compete in practically limitless numbers of other chemical analysis fields. All of these chemical tests are housed in one convenient, smart phone style device with interchangeable sensors depending on the type of material being tested. OrganaDx– Initially detects the most common pesticides linked to cancer to help consumers avoid harmful foods products. AquaDx– Tests for water contaminants, such as BPA, arsenic, uranium, and bacteria that can prove to be harmful to consumers over time. AeroDx– Measures elements of the Environmental Protection Agency"s Air Quality Index to determine the safety of indoor and outdoor air. CannaDx– Tests for 25 important chemicals found in cannabis, including cannabinoids and terpenes that could have medical importance. Looking Ahead MyDx trades with a market capitalization of just $22 million, which represents a fraction of its potential if successful in launching into just one of its target end markets. With an initial focus on cannabis, the company is filling a very real need in a rapidly growing market, while its commercialization strategy mirrors that of many other successful companies. The potential to move into other areas of personal chemical analysis represents icing on the proverbial cake. For more information, visit the company"s website at www.cdxlife.com. Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.